single grad
voted
🎉 Glad to inform SG mooers 🎉
The wait is almost over—just the last day to go until MooFest 2024!
>> Grab the last chance to joun us<<
We’re excited that you’ll be joining us for MooFest 2024, happening TOMORROW! We’ve planned an incredible day filled with activities for you to have fun and learn more about investing. To make sure that you're ready for a fantastic time, here is some important information you need.
📅 Date: 6 July 2024 (Tomorrow)
⏰ Time: 9am - 6pm...
The wait is almost over—just the last day to go until MooFest 2024!
>> Grab the last chance to joun us<<
We’re excited that you’ll be joining us for MooFest 2024, happening TOMORROW! We’ve planned an incredible day filled with activities for you to have fun and learn more about investing. To make sure that you're ready for a fantastic time, here is some important information you need.
📅 Date: 6 July 2024 (Tomorrow)
⏰ Time: 9am - 6pm...
+4
163
109
22
single grad
commented on
TLDR: if interest rate hike is only 0.25% or 0.5%, we can see a huge upswing in stock price. But if it is more than 0.75%, get ready to see a sea of red. If you are trading (be it long or short) be ready for huge volatility.
Explaination
The fed is announcing the interest rate hike at 2am SGT (2pm ET). When interest rate goes up price of stocks will drop, and vice versa. Why? I'll explain it in another post but for n...
Explaination
The fed is announcing the interest rate hike at 2am SGT (2pm ET). When interest rate goes up price of stocks will drop, and vice versa. Why? I'll explain it in another post but for n...
23
17
3
single grad
commented on
$Ardelyx (ARDX.US)$ shorts dipping it so they can cover. as long as it stays above 1.45 it will recover to 1.75
22
61
single grad
commented on
$Tesla (TSLA.US)$ the bounce lost its momentum!
2
1
moomooer! I opened this app after a longg time. everything 满江红. lol
single grad
commented on
$Ardelyx (ARDX.US)$ just one qn. I bought this stock at 1.405 and ever since I left it there but till now it has always been in the range from 1.21-1.24 or sometimes 1.25 and dropped to 1.1+ before so I mean I didn’t spend that much should I hold or just sell.
1
3
single grad
commented on
$Ardelyx (ARDX.US)$ This is a biopharmaceutical company, and its products have entered the later stages of clinical trials. In other words, success is not far away. Currently, its stock price is at the lowest level in history, and it won't be long before it rises like a rocket.
Translated
5
3
1
single grad
commented on
$Ardelyx (ARDX.US)$
Citigroup raised the price target on Ardelyx Inc (NASDAQ:ARDX) to $13 from $7, with a Buy rating unchanged.The update follows the Company's plans to launch Ibsrela (tenapanor) for irritable bowel syndrome with constipation (IBS-C) independently in Q2 2022. Analyst Yigal Nochomovitz added IBS-C revenues in the U.S. back to his model and noted that his estimates are in line with management's guidance for $500M at peak, which Nochomovitz sees coming in 2029. He also argues that the Ibsrela launch partially shifts the focus off the formal dispute resolution process with the FDA for hyperphosphatemia and gives Ardelyx another near-term catalyst.Ladenburg upgraded Ardelyx to Buy from Neutral with a $6 price target. Analyst Matthew Kaplan believes the product for IBS-C could generate greater than $400 million in revenues by 2026. Kaplan also notes that Ardelyx announced plans to file a Formal Dispute Resolution Request during Q4 to appeal the CRL for tenapanor for hyperphosphatemia. He looks forward to the filing of the FDRR and more detail on the path forward for this indication.
Citigroup raised the price target on Ardelyx Inc (NASDAQ:ARDX) to $13 from $7, with a Buy rating unchanged.The update follows the Company's plans to launch Ibsrela (tenapanor) for irritable bowel syndrome with constipation (IBS-C) independently in Q2 2022. Analyst Yigal Nochomovitz added IBS-C revenues in the U.S. back to his model and noted that his estimates are in line with management's guidance for $500M at peak, which Nochomovitz sees coming in 2029. He also argues that the Ibsrela launch partially shifts the focus off the formal dispute resolution process with the FDA for hyperphosphatemia and gives Ardelyx another near-term catalyst.Ladenburg upgraded Ardelyx to Buy from Neutral with a $6 price target. Analyst Matthew Kaplan believes the product for IBS-C could generate greater than $400 million in revenues by 2026. Kaplan also notes that Ardelyx announced plans to file a Formal Dispute Resolution Request during Q4 to appeal the CRL for tenapanor for hyperphosphatemia. He looks forward to the filing of the FDRR and more detail on the path forward for this indication.
6
2
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
![[loading]](data:image/svg+xml;base64,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)